Skip to Main Content

Acorda Therapeutics (ACOR) was turned away at the FDA’s doorstep when it tried to submit a marketing application for a new drug to treat Parkinson’s disease. The embarrassing regulatory miscue disclosed Tuesday will delay the drug’s approval.

Shares of Acorda fell 27 percent to $18.75 in Tuesday pre-market trading.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED